Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Current Deferred Revenue (2016 - 2025)

Traws Pharma (TRAW) has disclosed Current Deferred Revenue for 14 consecutive years, with $226000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Current Deferred Revenue changed 0.0% to $226000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $226000.0, a 0.0% change, with the full-year FY2024 number at $226000.0, changed 0.0% from a year prior.
  • Current Deferred Revenue was $226000.0 for Q1 2025 at Traws Pharma, roughly flat from $226000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $227000.0 in Q2 2024 to a low of $226000.0 in Q1 2021.
  • A 5-year average of $226058.8 and a median of $226000.0 in 2021 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: changed 0.0% in 2021, then rose 0.44% in 2024.
  • Traws Pharma's Current Deferred Revenue stood at $226000.0 in 2021, then changed by 0.0% to $226000.0 in 2022, then changed by 0.0% to $226000.0 in 2023, then changed by 0.0% to $226000.0 in 2024, then changed by 0.0% to $226000.0 in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Current Deferred Revenue are $226000.0 (Q1 2025), $226000.0 (Q4 2024), and $226000.0 (Q3 2024).